DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR(R)

Top-Line Data on Track for Q4 2017 CUPERTINO, Calif., June 22, 2017 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial... Biopharmaceuticals DURECT, POSIMIR, SABER, Bupivacaine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news